{"id":"NCT05027802","sponsor":"Ipsen","briefTitle":"A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.","officialTitle":"Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-03-14","primaryCompletion":"2024-11-30","completion":"2024-11-30","firstPosted":"2021-08-30","resultsPosted":"2025-06-13","lastUpdate":"2025-06-22"},"enrollment":61,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fibrodysplasia Ossificans Progressiva (FOP)"],"interventions":[{"type":"DRUG","name":"Palovarotene","otherNames":[]}],"arms":[{"label":"Palovarotene Chronic/Flare-Up Regimen","type":"EXPERIMENTAL"}],"summary":"The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP.\n\nThe aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator's judgement, may benefit from palovarotene therapy.","primaryOutcome":{"measure":"Number of Participants With All Treatment-emergent Adverse Events (TEAEs), Serious and Non-serious Treatment-emergent Adverse Events and Serious and Non-serious Treatment-related Treatment-emergent Adverse Events","timeFrame":"From signing the informed consent form (Day 1) up to 30 days post last dose, approximately 32 months","effectByArm":[{"arm":"Palovarotene","deltaMin":54,"sd":null}],"pValues":[]},"eligibility":{"minAge":"14 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":15},"locations":{"siteCount":13,"countries":["United States","Argentina","Australia","Brazil","Canada","France","Italy","Spain","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2025/06/11113724/CLIN-60120-452_Lay-Summary_Final_23May2025.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":59},"commonTop":["Dry skin","COVID-19","Fall","Skin abrasion","Back pain"]}}